NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing se… Read more
NeoGenomics Inc (NEO) - Total Assets
Latest total assets as of September 2025: $1.37 Billion USD
Based on the latest financial reports, NeoGenomics Inc (NEO) holds total assets worth $1.37 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NeoGenomics Inc - Total Assets Trend (2000–2024)
This chart illustrates how NeoGenomics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NeoGenomics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
NeoGenomics Inc's total assets of $1.37 Billion consist of 36.4% current assets and 63.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.4% |
| Accounts Receivable | $150.54 Million | 9.2% |
| Inventory | $26.75 Million | 1.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $339.68 Million | 20.7% |
| Goodwill | $522.77 Million | 31.9% |
Asset Composition Trend (2000–2024)
This chart illustrates how NeoGenomics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NeoGenomics Inc's current assets represent 36.4% of total assets in 2024, a decrease from 100.0% in 2000.
- Cash Position: Cash and equivalents constituted 22.4% of total assets in 2024, down from 100.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 31.9% of total assets.
NeoGenomics Inc Competitors by Total Assets
Key competitors of NeoGenomics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
NeoGenomics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - NeoGenomics Inc generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - NeoGenomics Inc is currently not profitable relative to its asset base.
NeoGenomics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.91 | 1.99 | 6.13 |
| Quick Ratio | 3.62 | 1.91 | 5.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $284.42 Million | $ 293.83 Million | $ 375.55 Million |
NeoGenomics Inc - Advanced Valuation Insights
This section examines the relationship between NeoGenomics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.72 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | -2.6% |
| Total Assets | $1.64 Billion |
| Market Capitalization | $933.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values NeoGenomics Inc's assets below their book value (0.57 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: NeoGenomics Inc's assets decreased by 2.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for NeoGenomics Inc (2000–2024)
The table below shows the annual total assets of NeoGenomics Inc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.64 Billion | -2.57% |
| 2023-12-31 | $1.68 Billion | -3.38% |
| 2022-12-31 | $1.74 Billion | -6.94% |
| 2021-12-31 | $1.87 Billion | +89.19% |
| 2020-12-31 | $988.33 Million | +39.30% |
| 2019-12-31 | $709.51 Million | +40.49% |
| 2018-12-31 | $505.01 Million | +47.09% |
| 2017-12-31 | $343.34 Million | +1.85% |
| 2016-12-31 | $337.12 Million | -8.38% |
| 2015-12-31 | $367.95 Million | +353.67% |
| 2014-12-31 | $81.11 Million | +103.19% |
| 2013-12-31 | $39.92 Million | +32.74% |
| 2012-12-31 | $30.07 Million | +50.74% |
| 2011-12-31 | $19.95 Million | +46.14% |
| 2010-12-31 | $13.65 Million | +5.45% |
| 2009-12-31 | $12.95 Million | +77.45% |
| 2008-12-31 | $7.30 Million | +11.88% |
| 2007-12-31 | $6.52 Million | +108.21% |
| 2006-12-31 | $3.13 Million | +189.97% |
| 2005-12-31 | $1.08 Million | +82.45% |
| 2004-12-31 | $592.00K | +16.76% |
| 2003-12-31 | $507.04K | +13.22% |
| 2002-12-31 | $447.84K | +450.56% |
| 2001-12-31 | $81.34K | +43632.80% |
| 2000-12-31 | $186.00 | -- |